Abstract Library

#3017 Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cella D

Authors: Feuilly M, Jenni E, Cella D,

Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,

#2168 Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors

Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan J, Faris J, Murphy J, Blaszkowsky L, McCleary N,

Keywords: cabozantinib, pancreatic neuroendocrine tumor, carcinoid, phase II,

#2147 Nutritional Assessment and Vitamin Deficiencies in Patients with NETs

Introduction: As a result of disease or related to its management, patients with neuroendocrine tumours may have altered gut or pancreatic function that can cause nutritional deficiencies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Lim S, Reynolds M, Rees D, Chaudhry R, Blackhouse J,

Keywords: Nutrition, Dietetics, Malnutrition, Vitamin Deficiency, Screening,

#1860 Carcinoid Heart Disease (CHD): Prognostic Value of 5-HIAA and Impact on Survival – A Systematic Literature Review

Introduction: CHD is a life threatening complication of carcinoid syndrome. Its exact pathophysiology is uncertain but several studies have identified serotonin as a potential key mediator. The amount of serotonin production can be assessed by the dosage of its metabolite 5-HIAA in urine or plasma.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Singh S

Authors: Haig J, Kohli M, Pastor L, Feuilly M, Marteau F,

Keywords: 5-HIAA, prognosis, carcinoid heart disease, survival,

#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial

Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cella D

Authors: Cella D, Beaumont J, Hudgens S, Marteau F, Feuilly M,

Keywords: telotristat ethyl, HRQoL, carcinoid syndrome,